• [[ Whitepaper ]] Connecting With Rare Disease Patient Communities: Patient Advocates

    laureng Whitepapers April 19, 2018
  • [[Whitepaper ]] Disruptive Innovation in Rare Disease Markets

    laureng Whitepapers April 19, 2018
  • Choosing the Right Channel Strategy for Specialty Product Success

    Karina Kusova Clinical Development, Market Access, Orphan Drug Congress, Supply Chain & Manufacturing, Uncategorized, Whitepapers May 3, 2017
  • [Whitepaper] Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies

    Karina Kusova Clinical Development, Orphan Drug Congress, Uncategorized, Whitepapers April 10, 2017
  • [[whitepaper]] The New Reality: Maximizing Value in Rare Disease Launches

    Karina Kusova Clinical Development, Featured on App, Orphan Drug Congress, Uncategorized, Whitepapers April 6, 2017
  • What’s New in Rare Cancer Research? (Spoiler Alert: A Lot!)

    Karina Kusova Advocacy, Clinical Development, Market Access, Orphan Drug Congress, Orphan Drugs Live October 10, 2016

Subscribe to Total Orphan Drugs

Strategy and innovation in the orphan drugs and rare diseases industry
Navigation
  • Development
  • Regulation
  • Advocacy
  • Market Access
  • Partnering & Investment
  • Whitepapers
  • Events
    • USA
  • Search
Biogen Idec

Tag Archive

View Post

Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis

In Press Release by CecileAugust 18, 2014Leave a Comment

− Reduces Relapses, Disability Progression and Brain Lesions with a Favorable Safety Profile  − Only Pegylated Interferon in MS, Dosed Once Every Two Weeks  − Complements …

View Post

PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis

In Press Release by CecileJuly 25, 2014Leave a Comment

  – Reduces Relapses, Disability Progression, and MRI Brain Lesions, with a Favorable Safety Profile Consistent with the Established Interferon Class  – Initial Country Launches …

View Post

Sobi to review preclinical data to potentially add future haemophilia A candidate to collaboration agreement with Biogen Idec

In Press Release by CameronJune 17, 2014Leave a Comment

June 17, 2014 On Friday, 13 June, Swedish Orphan Biovitrum AB’s (publ) (Sobi) received a data package from Biogen Idec regarding a preclinical Hemophilia A program based …

View Post

FDA Approves Biogen Idec’s ELOCTATE™, First Hemophilia A Therapy to Extend the Interval between Prophylactic Infusions, for Both Adults and Children

In Press Release by CameronJune 9, 2014Leave a Comment

Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Infusions Every Three to Five Days Approval of Biogen Idec’s Second Innovative Hemophilia Therapy with …

View Post

Data from Biogen Idec’s Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses

In Press Release by CameronJune 2, 2014Leave a Comment

Scientific Presentations Showcase Innovative MS Medicines and Experimental Therapies May 30, 2014 Biogen Idec today announced that more than 60 company-sponsored presentations highlighting key data from its …

View Post

Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 Pediatric Study of Investigational Therapy Eloctate™ for Hemophilia A

In Press Release by CameronApril 11, 2014Leave a Comment

Data Showed Twice-Weekly Prophylactic Dosing with ELOCTATE Maintained Low Bleeding Rates in Children Under Age 12 Study Meets Primary Objectives; Results Enable Regulatory Submission in …

View Post

FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart

In Press Release by CameronMarch 31, 2014Leave a Comment

Only Approved Treatment to Demonstrate Prolonged Clotting Factor Circulation in the Body – Approved for Adults and Children March 28, 2014 Today Biogen Idec announced that the U.S. …

View Post

Health Canada Approves Biogen Idec’s Long-Acting ALPROLIX Therapy for Hemophilia B

In Press Release by CameronMarch 24, 2014Leave a Comment

The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years March 21, 2014 Today Biogen Idec announced that Health Canada …

  • Page 1 of 2
  • 1
  • 2
  • →

Categories

  • Advocacy
  • Clinical Development
  • Featured on App
  • Market Access
  • Orphan Drug Congress
  • Orphan Drugs Live
  • Partnering & Investment
  • Press Release
  • Regulation & Government
  • Reports
  • Supply Chain & Manufacturing
  • Uncategorized
  • Whitepapers
Toggle the Widgetbar
World Orphan Drug Congress USA
  • Home
  • About Us/Advertise